title: Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia.
abstract: We analyzed the long-term outcomes of 1021 patients with acute lymphoblastic leukemia (ALL), enrolled in four successive clinical trials (ALL811, ALL841, ALL874 and ALL911) between 1981 and 1993. All patients received risk-adopted therapy according to leukocyte count and age at the time of diagnosis. The median follow-up durations of the four studies were 17.8 years in ALL811, 15.5 years in ALL841, 11.9 years in ALL874 and 15.8 years in ALL911. Patients' event-free survival (EFS) and overall survival (OS) rates at 12 years were 41.0 and 54.3% in ALL811, 50.2 and 60.2% in ALL841, 57.3 and 64.7% in ALL874, and 63.4 and 71.7% in ALL911, respectively. Thus, cure can become a reality for about 70% of children with ALL. There is, however, still a significant difference in survival outcomes according to risk group. Late effects were observed in 70 patients out of 834 (8.4%); hepatitis and short stature were most commonly reported. Reduction of late adverse effects for all patients and development of new treatment strategies for very-high-risk patients are major issues for upcoming trials to address.
authors.affiliation: Department of Pediatrics, Aichi Medical University, Aichi, Japan. mtsuru@aichi-med-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Tsurusawa
authors.forename: Y
authors.initials: Y
authors.lastname: Shimomura
authors.forename: K
authors.initials: K
authors.lastname: Asami
authors.forename: A
authors.initials: A
authors.lastname: Kikuta
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Horikoshi
authors.forename: T
authors.initials: T
authors.lastname: Matsushita
authors.forename: H
authors.initials: H
authors.lastname: Kanegane
authors.forename: S
authors.initials: S
authors.lastname: Ohta
authors.forename: A
authors.initials: A
authors.lastname: Iwai
authors.forename: H
authors.initials: H
authors.lastname: Mugishima
authors.forename: S
authors.initials: S
authors.lastname: Koizumi
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan; D008297:Male; D008495:Medical Oncology / Q000458:organization & administration; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome